Login / Signup

Postmarketing safety and effectiveness of recombinant factor IX (nonacog alfa) in Japanese patients with haemophilia B.

Katsuyuki FukutakeMasashi TakiTadashi MatsushitaMichio SakaiAmi TakataHiromi YamaguchiToshiyuki Karumori
Published in: Haemophilia : the official journal of the World Federation of Hemophilia (2019)
Nonacog alfa therapy is safe and effective in the real-world scenario in Japan.
Keyphrases
  • replacement therapy
  • randomized controlled trial
  • systematic review
  • smoking cessation
  • bone marrow
  • mesenchymal stem cells